



**HAL**  
open science

## Long-term air pollution exposure is associated with increased severity of rhinitis in 2 European cohorts

Emilie Burte, Bénédicte Leynaert, Alessandro Marcon, Jean Bousquet, Meriem Benmerad, Roberto Bono, Anne-Elie Carsin, Kees de Hoogh, Bertil Forsberg, Frederic Gormand, et al.

### ► To cite this version:

Emilie Burte, Bénédicte Leynaert, Alessandro Marcon, Jean Bousquet, Meriem Benmerad, et al.. Long-term air pollution exposure is associated with increased severity of rhinitis in 2 European cohorts. *Journal of Allergy and Clinical Immunology*, 2020, 145 (3), pp.834-+. 10.1016/j.jaci.2019.11.040 . hal-02565460

HAL Id: hal-02565460

<https://univ-rennes.hal.science/hal-02565460v1>

Submitted on 7 Mar 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## Long-term air pollution exposure is associated with increased severity of rhinitis in two European cohorts

Burte E, PhD<sup>1,2,3,4</sup>, Leynaert B, PhD<sup>5</sup>, Marcon A, PhD<sup>6</sup>, Bousquet J, MD<sup>1,2,7</sup>, Benmerad M, MSc<sup>8</sup>, Bono R, PhD<sup>9</sup>, Carsin AE, MSc<sup>3,4,10,11</sup>, de Hoogh K, PhD<sup>12,13</sup>, Forsberg B, PhD<sup>14</sup>, Gormand F, MD<sup>15</sup>, Heinrich J, PhD<sup>16,17</sup>, Just J, MD<sup>18,19</sup>, M Nieuwenhuijsen, PhD<sup>3,4,10,11</sup>, Pin I, MD<sup>8,20</sup>, Stempfelet M, MSc<sup>21</sup>, Sunyer J, MD, PhD<sup>3,4,10,11</sup>, Villani S, PhD<sup>22</sup>, Künzli N, PhD<sup>12,13</sup>, Siroux V, PhD<sup>8</sup>, Jarvis D, MD, PhD<sup>23,24</sup>, Nadif R, PhD<sup>1,2\*</sup>, Jacquemin B, MD, PhD<sup>1,2,3,10\*</sup>

\* These authors contributed equally to this study

1. INSERM, U1168, VIMA: Aging and chronic diseases. Epidemiological and public health approaches, Villejuif, France
2. Univ Versailles St-Quentin-en-Yvelines, UMR 1168, F-78180, Montigny le Bretonneux, France
3. ISGLocal, Barcelona, Spain.
4. Universitat Pompeu Fabra (UPF), Barcelona, Spain.
5. Inserm, UMR 1152, Pathophysiology and Epidemiology of Respiratory Diseases, Paris, France;
6. Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona;
7. University Hospital, Montpellier, France; MACVIA-France, Contre les MALadies Chroniques pour un Vieillissement Actif en France, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier;
8. Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Inserm U1209, CNRS, University Grenoble Alpes, Institute for Advanced Biosciences (IAB), Grenoble, France
9. Dept of Public Health and Pediatrics, University of Turin, Turin.
10. CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
11. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
12. Swiss Tropical and Public Health Institute, Basel, Switzerland
13. University of Basel, Basel, Switzerland
14. Dept of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
15. CHU de Lyon, Pneumology Dept, Lyon, France.
16. Ludwig Maximilians University Munich, University Hospital Munich, Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Munich, Germany
17. Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research
18. Allergology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Armand-Trousseau
19. Sorbonne Université Paris 6, Paris, France
20. Pédiatrie, CHU de Grenoble Alpes, Grenoble, France.
21. Santé Publique France, 12, rue du Val d'Osne, 94415 Saint-Maurice, France.
22. Unit of Biostatistics and Clinical Epidemiology, Dept of Public Health, Experimental and Forensic Medicine University of Pavia, Pavia.
23. National Heart and Lung Institute, Imperial College London, London, United Kingdom
24. MRC Centre for Environment and Health, School of Public Health, London, United Kingdom

## **Acknowledgment and Funding:**

### **Funding:**

ECRHS was supported by the European Commission, as part of their Quality of Life program.

The following bodies funded the local studies in ECRHS III in this article:

**Belgium: Antwerp South, Antwerp City:** Research Foundation Flanders (FWO), grant code G.0.410.08.N.10 (both sites), **France: (All)** Ministère de la Santé. Programme Hospitalier de Recherche Clinique (PHRC) national 2010 **Grenoble:** Comite Scientifique AGIRadom 2011. **Paris:** Agence Nationale de la Santé, Région Ile de France, domaine d'intérêt majeur (DIM) **Germany :** **Erfurt:** German Research Foundation HE 3294/10-1 **Italy:** All Italian centres were funded by the Italian Ministry of Health, Chiesi Farmaceutici SpA, in addition **Verona** was funded by Cariverona foundation, Education Ministry (MIUR). **Spain:** Fondo de Investigación Sanitaria (PS09/02457, PS09/00716 09/01511) PS09/02185 PS09/03190), Servicio Andaluz de Salud , Sociedad Española de Neumología y Cirugía Torácica (SEPAR 1001/2010); **Barcelona:**Fondo de Investigación Sanitaria (FIS PS09/00716) **Galdakao:** Fondo de Investigación Sanitaria (FIS 09/01511) **Huelva:** Fondo de Investigación Sanitaria (FIS PS09/02185) and Servicio Andaluz de Salud **Oviedo:** Fondo de Investigación Sanitaria (FIS PS09/03190) **Sweden:** All centres were funded by The Swedish Heart and Lung Foundation, The Swedish Asthma and Allergy Association, The Swedish Association against Lung and Heart Disease. Swedish Research Council for health, working life and welfare (FORTE), **UK:** Medical Research Council (Grant Number 92091). Support also provided by the National Institute for Health Research through the Primary Care Research Network

EGEA is funded in part by PHRC-Paris, PHRC-Grenoble, ANR 05-SEST-020-02/05-9-97, ANR-06-CEBS, ANR-CES-2009, Région Nord Pas-de-Calais, Merck Sharp & Dohme (MSD)

ESCAPE Funding: The research leading to these results has received funding from the European Community's Seventh Framework Program (FP7/2007-2011) under grant agreement number: 211250.

### **Acknowledgment:**

#### **ECRHS**

The ECRHS data incorporated in this analysis would not have been available without the collaboration of the following individuals and their research teams.

**ECRHS Co-ordinating centre:** P Burney, D Jarvis, S Chinn, J Knox (ECRHS II), C Luczynska+ , J Potts.

**Principal Investigators and Senior Scientific Teams for ECRHS III:** Belgium: South Antwerp & Antwerp City (J. Weyler, H.Bentouhami, V. Nelen ) France: Grenoble (I. Pin, V. Siroux, J.Ferran, J.L

Cracowski) Paris (B. Leynaert, D. Soussan, D. Courbon, C. Neukirch, L. Alavoine, X. Duval, I. Poirier) Germany: Erfurt (J. Heinrich, E. Becker, G. Woelke, O. Manuwald), Italy: Pavia (I. Cerveri, A. Corsico, A. Grosso, F. Albicini, E. Gini, E.M Di Vincenzo, V. Ronzoni, S. Villani, F. Campanella, M. Gnesi, F. Manzoni, L. Rossi, O. Ferraro) Turin: (M. Bugiani, R. Bono, P. Piccioni, R. Tassinari, V. Bellisario, G. Trucco) Verona: (R de Marco†, S. Accordini, L. Calciano, L. Cazzoletti, M. Ferrari, A.M Fratta Pasini, F. Locatelli, P. Marchetti, A. Marcon, E. Montoli, G. Nguyen, M. Olivieri, C. Papadopoulou, C. Posenato, G. Pesce, P. Vallerio, G. Verlato, E. Zanolin), Norway: (C. Svanes, E. Omenaas, A. Johannessen, T. Skorge, F. Gomez Real) Spain: Barcelona:(J-M. Antó, J.P Zock, J Garcia-Aymerich, M Kogevinas, X. Basagaña, A.E. Carsin, F. Burgos, C. Sanjuas, S Guerra, B. Jacquemin, P.Davdand Galdakao: N. Muñozguren, I. Urrutia, U. Aguirre, S. Pascual) Huelva:(Antonio Maldonado, A. Pereira, J. Luis Sánchez, L. Palacios, Oviedo: (F. Payo, I. Huerta, N. Sánchez, M. Fernández, B. Robles) Sweden: Umea (B. Forsberg, L. Braback, L. Modig, B. Järholm, H Bertilsson, K.A Franklin, C Wahlgreen), UK: Ipswich: ( N. Innes) Norwich: (A. Wilson)

#### EGEA:

**Coordination:** V Siroux (epidemiology, PI since 2013); F Demenais (genetics); I Pin (clinical aspects); R Nadif (biology); F Kauffmann (PI 1992-2012). **Respiratory epidemiology:** Inserm ex-U 700, Paris: M Korobaëff (Egea1), F Neukirch (Egea1); Inserm ex-U 707, Paris: I Annesi-Maesano (Egea1-2); Inserm ex-U 1018, Villejuif: F Kauffmann, MP Oryszczyn (Egea1-2); Inserm U 1168, Villejuif: N Le Moual, R Nadif, R Varraso; Inserm U 1209 Grenoble: V Siroux. **Genetics:** Inserm ex-U 393, Paris: J Feingold; Inserm U 946, Paris: E Bouzigon, F Demenais, MH Dizier; CNG, Evry: I Gut (now CNAG, Barcelona, Spain), M Lathrop (now Univ McGill, Montreal, Canada). **Clinical centers:** Grenoble: I Pin, C Pison; Lyon: D Ecochard (Egea1), F Gormand, Y Pacheco; Marseille: D Charpin (Egea1), D Vervloet (Egea1-2); Montpellier: J Bousquet; Paris Cochin: A Lockhart (Egea1), R Matran (now in Lille); Paris Necker: E Paty (Egea1-2), P Scheinmann (Egea1-2); Paris-Trousseau: A Grimfeld (Egea1-2), J Just. **Data and quality management:** Inserm ex-U155 (Egea1): J Hochez; Inserm U 1168, Villejuif: N Le Moual; Inserm ex-U780: C Ravault (Egea1-2); Inserm ex-U794: N Chateigner (Egea1-2); Grenoble: J Quentin (Egea1-2).

We are indebted to the participants of EGEA3 and ECRHS III for their willingness to help with the collection of data.

#### **Conflict of interest:**

Pr. JUST reports personal fees and grants from Novartis and Astrazeneca, personal fees from GSK, Sanofi and ALK , outside the submitted work.

Pr Bousquet is a member of POLLAR (Impact of air POLLution on Asthma and Rhinitis, EIT Health).

The other authors have no conflict of interest to disclose related to this work.

**Corresponding author:**

Bénédicte Jacquemin, MD, PhD

Irset - Inserm UMR\_S 1085

9 avenue du Prof. Léon Bernard

35000 RENNES

FRANCE

[Tel:+33 \(0\)2 23 23 77 69](tel:+33223237769)

Mail: [benedicte.jacquemin@inserm.fr](mailto:benedicte.jacquemin@inserm.fr)

## **Abstract:**

**Background:** Very few studies have examined the association between long-term outdoor air pollution and rhinitis severity in adults.

**Objective:** To assess the cross-sectional association between individual long-term exposure to air pollution and severity of rhinitis.

**Methods:** Participants with rhinitis from two multicentre European cohorts (EGEA and ECRHS) were included. Annual exposure to NO<sub>2</sub>, PM<sub>10</sub>, PM<sub>2.5</sub> and PM<sub>coarse</sub> (calculated by subtracting PM<sub>2.5</sub> from PM<sub>10</sub>) was estimated using land-use regression models derived from the ESCAPE project, at the participants' residential address. The score of rhinitis severity (range 0-12), based on intensity of disturbance due to symptoms reported by questionnaire, was categorized in low (reference), mild, moderate and high severity. Polytomous logistic regression models with a random intercept for city were used.

**Results:** 1408 adults with rhinitis (mean age: 52 years, 46% men, 81% from ECRHS) were included. The median [Q1-Q3] score of rhinitis severity was 4 [2-6]. Higher exposure to PM<sub>10</sub> was associated with higher rhinitis severity (aOR[95% CI] for a 10 µg/m<sup>3</sup> increase of PM<sub>10</sub>: for mild: 1.20[0.88-1.64], moderate: 1.53[1.07-2.19], and high severity: 1.72[1.23-2.41]). Similar results were found for PM<sub>2.5</sub>. Higher exposure to NO<sub>2</sub> was associated with an increased severity of rhinitis, with similar aORs whatever the level of severity. aORs were higher among participants without allergic sensitization than in those with, but interaction was found only for NO<sub>2</sub>.

**Conclusions:** People with rhinitis who live in areas with higher levels of pollution are more likely to report more severe nasal symptoms – further work is required to elucidate the mechanisms of this association.

**Total word count:** 251

**Capsule summary:** People with rhinitis who live in areas with higher levels of pollution are more likely to report more severe nasal symptoms – further work is required to elucidate the mechanisms of this association.

**Key messages:**

- Very little is known about air pollution as risk factor for rhinitis and its phenotypes in adults
- Air pollution and particularly particulate matter is associated with an increase in rhinitis severity
- Air pollution needs to be controlled

**Keywords:** rhinitis, allergic sensitization, air pollution, environment, severity, respiratory disease

**Abbreviations:**

ARIA: Allergic Rhinitis and its Impact on Asthma

ECRHS: European Community Respiratory Health Survey

EGEA: Epidemiological Study on the Genetics and Environment on Asthma

ESCAPE: European Study of Cohorts for Air Pollution Effects

LUR: Land-Use Regression

NO<sub>2</sub>: nitrogen dioxide

OR: Odds Ratio

PM: Particulate matter

SAR: Seasonal Allergic Rhinitis

## Introduction

Rhinitis is a very frequent disease affecting between 20% and 50% of the population according to countries and definitions (1–3). The principal symptoms of rhinitis are sneezing and runny, blocked or itchy nose, in absence of a cold or the flu (4). Often considered as a trivial disease, rhinitis does actually have an important impact on quality of life (5,6). Rhinitis is generally divided into allergic and non-allergic rhinitis, often differing in terms of symptoms, duration, treatment, seasonality and/or severity (7,8). Very little is known about the environmental risk factors of rhinitis and its different phenotypes, including air pollution (9). As rhinitis is frequently associated with asthma (10) for which air pollution has been shown to strongly aggravate symptoms (11), and even induce the disease (12), it is a genuine question to wonder about the effects of air pollution on rhinitis.

There are very few studies focusing on the association between air pollution and rhinitis in adults. Short-term exposure to air pollution has been associated with exacerbation of rhinitis leading to more daily clinical examinations (13,14). However, association between long-term air pollution and rhinitis severity has scarcely been studied. One large French study assessing the link between grass pollen counts, air pollution levels and severity of seasonal allergic rhinitis found a positive but not statistically significant association between air pollutant level and severe allergic rhinitis (15). However, this study only considered seasonal allergic rhinitis and no other phenotypes. Recently, an American study examined the relationship between PM<sub>2.5</sub> (airborne particles with an aerodynamic diameter  $\leq 2.5$   $\mu\text{m}$ ) and black carbon and rhinitis in 125 patients with chronic rhinosinusitis with and without polyps (16). They found significantly higher exposure levels of PM<sub>2.5</sub> and black carbon among participants without allergic sensitization compared to those with allergic sensitization, and also found an association between black carbon and non-allergic symptoms of rhinitis. In a previous study, we found no consistent evidence for an association between long-term exposure to air pollution and incidence of rhinitis, whether allergic or non-allergic (17). We hypothesized that air pollution may not induce rhinitis development, but may still be associated with an increase in severity of the disease.

In the present study, we aimed to examine the association between long term exposure to air pollution and severity of allergic and non-allergic rhinitis in two European studies.



## Methods:

### **Study design and settings**

Participants included in the analysis were those suffering from rhinitis at the second follow-up (2011-2013) of two large multicentre epidemiological European studies: the European Community Respiratory Health Survey (ECRHS) and the Epidemiological Study on the Genetics and Environment on Asthma (EGEA).

The EGEA ((18,19), <https://egeanet.vjf.inserm.fr/>) is a French cohort of 2,047 participants (asthma patients –adults or children- enrolled from hospital chest clinics, their first-degree relatives, and controls who were recruited from other hospital wards or from electoral lists) enrolled between 1991 and 1995 from five French cities. A first follow-up was conducted between 2003 and 2007 (EGEA2, N=2121, (19,20)) and a second between 2011 and 2013 (EGEA 3, N=1558, (21)).

The ECRHS (22) is a population-based cohort of young adults, enriched with participants with respiratory symptoms, recruited from 1992 to 1994 in 28 western European cities (ECRHS I, N=17880, <http://www.ecrhs.org/>) and followed up twice: between 2000 and 2002 (ECRHS II, n=10933, (23)) and between 2011 and 2013 (ECRHS III, N=7040).

Participants of both studies were extensively characterized with regard to their respiratory health and risk factors using similar standardized protocols and questionnaires. Ethical approval was obtained in each study from the appropriate institutional ethics committees and written informed consent was obtained from each participant.

### **Definition of rhinitis**

In this cross-sectional analysis, report of ever rhinitis was defined by a positive response to “*Have you ever had a problem with sneezing, or a runny or a blocked nose when you did not have a cold or the flu?*” in EGEA3 and ECRHS III.

Among those who had reported ever rhinitis, rhinitis in the last 12 months was defined by a positive response to “*Have you ever had a problem with sneezing, or a runny or a blocked nose when you did not have a cold or the flu in the last 12 months?*” in EGEA3 and ECRHS III.

### **Definition of score of severity of rhinitis (based on symptoms of rhinitis)**

A numeric score of severity of rhinitis was assessed at EGEA3 and ECRHSIII, adapted from the Symptomatic Global Score for seasonal allergic rhinitis (24). This score was calculated on the basis of the answers to question on severity of the four main symptoms of rhinitis (watery runny nose, blocked nose, itchy nose and sneezing). In case of missing data for severity of one or more symptoms, no imputation was done and these participants were not included in the analyses. For each of the four items, participants had to indicate how important the symptom had hampered their daily life in the last 12 months:

0. No problem (symptom not present)
1. A problem that is/was present but not disturbing
2. A disturbing problem but not hampering day time activities or sleep
3. A problem that hampers certain activities or sleep

Each question scored from 0 to 3 and thus summing the answers to these 4 questions, the overall score ranged from 0 to 12, the higher score indicating a higher severity. The overall score was further categorized into four levels according to the quartiles of the distribution: low severity (score  $\leq 2$ ), mild severity (score = 3 or 4), moderate severity (score = 5 or 6) and high severity (score  $\geq 7$ ). Low severity was considered as the reference in the analyses.

Additionally, severity was analysed symptom by symptom, using the following classification to approximate closely the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (2): The category 0 was considered as the reference compared to mild rhinitis (1), and moderate/severe rhinitis (2/3 pooled together).

### **Definition of allergic sensitization**

In EGEA2, allergic sensitization was defined using skin-prick test (SPT) for 12 aeroallergens (mean wheal diameter 3mm  $\geq$  than the negative control to at least one of the following allergens: cat, *Dermatophagoides pteronyssinus*, *Blattella germanica*, olive, birch, *Parietaria judaica*, timothy grass, ragweed pollen, *Aspergillus*, *Cladosporium herbarum*, *Alternaria tenuis*).

In ECRHS II, allergic sensitization was defined using specific Immunoglobulin E (IgE) to four allergens (specific IgE $\geq$ 35kU/mL to at least one of the following allergens: cat, *Dermatophagoides pteronyssinus*, *Cladosporium*, and timothy grass).

### **Definition of asthma**

Ever asthma was defined by a positive response to “*Have you ever had asthma?*” in ECRHS III; and by a positive response to one of the following questions “*Have you ever had attacks of breathlessness at rest with wheezing?*” or “*Have you ever had asthma attacks?*” at EGEA1, EGEA2 or EGEA3 or by being recruited as asthmatic cases in EGEA 1 (25).

### **Estimation of air Pollution exposure**

Long-term exposure to pollutants was estimated using land use regression models derived from the European Study of Cohorts for Air Pollution Effects (ESCAPE [www.escapeproject.eu](http://www.escapeproject.eu) (26,27)) project. The home addresses of the participants at EGEA2 and ECRHS II, living in ESCAPE cities were geocoded. As no exposure data at the same year of EGEA2 or ECRHS II was available, the exposure at the closest year was used. Therefore, geocodes were linked with ambient concentrations of air pollutants estimated using land-use regression (LUR) models between 2009 and 2010. Available air pollutants were: NO<sub>2</sub> (nitrogen dioxide), PM<sub>10</sub> (airborne particles with an aerodynamic diameter  $\leq$ 10  $\mu$ m), PM<sub>2.5</sub> and PM<sub>coarse</sub> (airborne particles with an aerodynamic diameter ranging from 2.5 to 10 $\mu$ m, calculated by subtracting PM<sub>2.5</sub> from PM<sub>10</sub>). Estimates of NO<sub>2</sub> were available for all 17 cities (Umea, Norwich, Ipswich, Antwerp, Erfurt, Paris, Lyon, Grenoble, Marseille, Verona, Pavia, Turin, Oviedo, Galdakao, Barcelona, Albacete and Huelva) and estimates of all PM metrics for 6 cities (Norwich, Ipswich, Antwerp, Paris, Grenoble, Turin and Barcelona). Data on two traffic exposure indicators -traffic intensity (on the nearest road), and traffic load (in a 100m buffer)- were also available.

### **Statistical analysis**

Associations between long-term exposure to air pollutants (estimated at participants' residential addresses at the first follow-up of each study, thus between 2000 and 2007) and the

severity score of rhinitis (assessed at the second follow-up of each study, thus between 2011 and 2013) were analysed using polytomous logistic regression. To account for between-city heterogeneity, a random intercept for city was used (GLLAMM procedure in STATA14).

Models were carried out without any adjustment, and then adjusted on pre-selected variables based on previous literature: age, sex, smoking status, asthma and allergic sensitization. Analyses with traffic density or traffic load were further adjusted for NO<sub>2</sub> background level as described in the ESCAPE protocol. Results are presented as odds ratio (OR) with the associated 95% confidence interval associated. Estimates were reported for an increase of 10 µg/m<sup>3</sup> for NO<sub>2</sub> and PM<sub>10</sub>, 5 µg/m<sup>3</sup> for PM<sub>2.5</sub> and PM<sub>coarse</sub>, 4,000,000 vehicles\*m/day for traffic load on all major roads in a 100m buffer and 5,000 vehicles/day for traffic density on the nearest road, following ESCAPE protocol.

Considering that air pollution may act differently according to allergic sensitization, a stratified analysis on allergic sensitization status was carried out. As air pollution is known to increase asthma severity and as asthma and rhinitis are strongly related, a stratified analysis on asthma status was also carried out. Smokers have a continual bombardment of the nasal cavities with PM and irritant gases from cigarette smoke, which could affect pollutant response and thus a stratified analysis on smoking status (current smokers vs. ex or never smokers) was carried out. Finally, since the design of ECRHS and EGEA differed, a stratified analysis on study was also carried out on the study. The interactions between each pollutant and each factor of stratification were tested by likelihood ratio tests in separate models.

To test if association between air pollution and severity of rhinitis differs according to the type of symptom, the association between air pollutants and severity of each of the four symptoms separately was estimated.

Sensitivity analyses were performed: as treatment may have lowered severity, analysis excluding participants with medication in the last 12 months (use of medication –pills or spray- to treat nasal disorder in the last 12 months) was performed. Given that the methods used to take into account the within-city (or centre) correlation is a complex issue (28), and to ensure robustness of our results, simple polytomous regressions without adding a city level intercept were also performed. As participants may have moved between the first and the second follow-up of both studies, we also performed the fully adjusted analysis among non-movers only to ensure robustness of the results. Since only half of the population has PM data

and to ensure comparability of the results, analyses with NO<sub>2</sub> were also performed in the restricted population with PM exposure data.

Bi-pollutant models including NO<sub>2</sub> and each one of the PM metrics were also performed to test the independence of the results for each of the pollutant.

All analyses were carried out by Stata (Stata 14)).

## Results:

This study included 1408 participants from EGEA3 and ECRHS III with symptoms of rhinitis in the last 12 months, having available data on rhinitis severity score and individual air pollution estimates (Flow-chart available in Figure 1).

A detailed description of the characteristics of the 1408 participants is reported in Table 1, for all participants and according to the four levels of severity of rhinitis. ECRHS contributed with 81% of the study population. Participants were on average 52.3 years old, 54.4% were women and 28% had asthma. The median severity score of rhinitis was 4 ([Q1-Q3]=[2-6]). When increasing in the severity category, participants were younger, more often from the EGEA study, and more often had asthma and allergic sensitization (from 18% in low severity to 39% in high severity and from 35% in low severity to 64% in high severity respectively). Participants with higher severity also reported allergic rhinitis or hay fever more often (from 34% for low severity to 81% for high severity) as well as more frequent symptoms of rhinitis.

An increase in air pollution exposure was associated with an increased in the severity of rhinitis (Figure 2, exact ORs in Table S2 in Supplementary material). Increased levels of PM<sub>10</sub> and PM<sub>2.5</sub> were associated with higher levels of severity, with an exposure-response association. A similar pattern was found for PM<sub>coarse</sub> with a slightly lower effect and reaching statistical significance only for high severity. For NO<sub>2</sub>, there was no exposure-response relationship. ORs for mild, moderate and high severity were similarly estimated at around 1.15. No association was found between traffic load or traffic intensity and score of severity.

### *Stratified analyses*

#### Stratification by allergic sensitization

Among participants with no allergic sensitization, increase in NO<sub>2</sub>, PM metrics and traffic intensity exposure were associated with an increased severity score of rhinitis, with an exposure-response relationship (Figure 3 and Table S2 in Supplementary material). Among participants with allergic sensitization, increase in air pollution exposure was associated with an increased severity score of rhinitis only for PM<sub>2.5</sub>. No association was found for the other pollutants. A statistically significant interaction was found between allergic sensitization and NO<sub>2</sub> (p-interaction of the likelihood-ratio test= 0.02), at borderline statistical significance for traffic load (p-interaction=0.05) and traffic intensity (p-interaction=0.08), and not statistically significant for PM<sub>10</sub> (p-interaction=0.26), PM<sub>2.5</sub> (p-interaction=0.21) and PM<sub>coarse</sub> (p-interaction=0.24).

#### Stratification by asthma status

Among the participants without asthma, an increase in air pollution exposure was associated with an increased severity score of rhinitis -similar to the results of the participants without allergic sensitization-(Table S2 in Supplementary material). In contrast, in the participants with asthma, an increase in air pollution exposure was not associated with an increased severity score of rhinitis – similar to the results of the participants with allergic sensitization. An interaction was found for NO<sub>2</sub> (p-interaction =0.007) and for traffic load (p-interaction=0.03) and no interaction was found between other pollutants and asthma (p-interactions>0.11).

#### Stratification by smoking status

Among non-smokers, a higher air pollution exposure was associated with an increased severity score of rhinitis (Table S3 in Supplementary material). In contrast, higher exposure was not associated with an increased severity score in smokers although all interaction tests were below conventional levels of significance (p-interactions <0.14)

#### Stratification by study

Among participants from the ECRHS study, higher air pollution exposure was associated with an increased severity score of rhinitis (Table S3 in Supplementary material). In contrast, a higher exposure was not associated with an increased severity score in participants from the EGEA study although all interaction tests were below conventional levels of significance (p-interactions <0.40).

### *Analyses of the association between air pollutants exposure and severity of each symptom of rhinitis*

The associations between air pollutants exposure and the symptoms composing the score are shown in Table S1 of the Supplementary material. In summary, PM<sub>10</sub> and PM<sub>2.5</sub> exposure increased the severity of blocked nose, itchy nose and sneezing, with an exposure-response relationship. NO<sub>2</sub> exposure increased the severity of runny and blocked nose when compared to no symptoms, with a similar effect size for moderate/severe or mild symptoms. No association was found between NO<sub>2</sub> exposure and severity of itchy nose and sneezing. No association was found between PM<sub>coarse</sub> exposure and severity of any of the four symptoms. No association was found between traffic load or traffic intensity and severity of any of the four symptoms.

### *Sensitivity analyses*

When considering only the participants who did not take medicine for rhinitis in the last 12 months, results were similar to those from the main analysis, with a dose-relationship for PM (Table S4 in Supplementary material). Analyses among non-movers only showed similar results to those from the main analysis, with even higher ORs for NO<sub>2</sub> and PM metrics (Table S5 in Supplementary material).

In the bi-pollutants models (Table S6 in Supplementary Material), results remained consistent for PM metrics, with higher OR but wider confidence intervals, leading to only two statistically significant ORs: for high level of severity for PM<sub>10</sub> and PM<sub>2.5</sub> (Pearson correlation between NO<sub>2</sub> and PM<sub>2.5</sub>=0.60, between NO<sub>2</sub> and PM<sub>10</sub>=0.70, and NO<sub>2</sub> and PM<sub>coarse</sub>=0.72). Interestingly, estimates for NO<sub>2</sub> in the bi-pollutant models with PM<sub>10</sub> and PM<sub>coarse</sub> were higher than those in the main model and were reaching statistical significance for almost all level of severity.

Unadjusted models or models without taking city level into account gave very similar results as those using adjusted model with a random intercept for city, without changing the statistical significance of the results (results not shown).

Analyses with NO<sub>2</sub> in the restricted population having PM exposure data gave similar results (results not shown).

## Discussion

In 1,408 participants from two European studies with detailed characterization of rhinitis, we investigated the association between individual air pollution exposure and severity of rhinitis. An increase in PM<sub>10</sub> and PM<sub>2.5</sub> exposure was associated with an increased severity of rhinitis. To a lesser extent, PM<sub>coarse</sub> and NO<sub>2</sub> were also associated with severity of rhinitis, with no exposure-response relationship for NO<sub>2</sub>. No association was found between traffic load or traffic intensity and severity of rhinitis.

Our study is one of the first to examine the long-term effects of air pollution on the severity of rhinitis, considering separately allergic and non-allergic rhinitis separately. Previously, a French study among 17,567 children and adults has modelled the risk of suffering from severe seasonal allergic rhinitis (SAR) as a function of both grass pollen count and outdoor air pollution evaluated by daily mean exposure over a period of a few months (15). They found a positive but not statistically significant association between NO<sub>2</sub> or PM<sub>10</sub> exposure and SAR high severity, with a trend for PM<sub>10</sub>, and with adjustment for pollen count. Findings from this study cannot be directly compared with our study given the differences in the phenotype studied, in the definition of severity as they considered high versus no, low or moderate severity, in the estimation of exposure to air pollution, and given the lack of results without adjustment on grass pollen. Nevertheless, our results for PM<sub>10</sub> and PM<sub>2.5</sub> among participants with allergic sensitization seem to be in line with this previous study. Unfortunately, we did not have data on grass pollen to take into account their interrelation with air pollutants in the study of allergic rhinitis.

One of the weaknesses of our study is the time discrepancy between ESCAPE measurement and the follow-up dates of the two studies: individual addresses were collected between 2000 and 2007, air pollution was measured and modelled between 2009 and 2010 and severity of rhinitis was collected between 2011 and 2013. Although the temporality -exposure assessment before severity assessment- is respected, we did not have the annual exposure corresponding to the year before questionnaire completion. This is a common problem when dealing with estimation of long-term annual air pollution. We assume that spatial variability of that specific year also represents the spatial patterns during previous years (29). Our results among non-movers were similar to those from the main analysis, with even higher ORs, strengthening the robustness of our results.



One of the strength of the present analysis is the appraisal of allergic and non-allergic rhinitis phenotypes, of rhinitis severity as well as the consideration of different types of symptoms. We found differences in the association between air pollution exposure and severity of rhinitis according to the phenotype studied. After stratification by allergic sensitization, the effect of pollutants seemed higher among participants without allergic sensitization than in those with, although that interaction was statistically significant only for NO<sub>2</sub>. The interactions between PM metrics and allergic sensitization were not statistically significant. However, we may not have enough power to find an interaction, as the sample size is almost half for PM analyses compared to NO<sub>2</sub> analyses. The higher association among participants without allergic sensitization could be partly supported by the fact that allergic sensitization is already a risk factor for high severity: there are twice as many participants with allergic sensitization with a high severity of rhinitis compared to low severity. The effect of pollutants may have a lower impact on those with already severe rhinitis. However, as discussed before, no association was found in the study by Annesi-Maesano et al. (15) between air pollution levels and score of allergic rhinitis. In the study by Mady et al., a positive correlation was found between exposure to black carbon and some symptoms of rhinitis, regardless of allergic sensitization status, and no results were available for PM<sub>2.5</sub>. Furthermore, this study was based on a small selected sample of patients with disease, without formal statistical analyses. We had no data on the seasonality of the symptoms, and thus we were not able to assess whether air pollution exposure had a different impact on severity of rhinitis, depending on seasonal or “throughout the year” symptoms. We had data on the long-term annual exposure of air pollution and this study was not designed to investigate short-term/ seasonal variation in nasal symptoms according to air pollutant levels.

Accounting for asthma when assessing the association between air-pollution and rhinitis is not trivial as rhinitis and asthma are strongly related, and air pollution is known to increase asthma severity and incidence. Our results were similar when adjusting or not adjusting for asthma. Stratified analyses on asthma showed a higher effect of air pollutant among participants without asthma, but the interaction was statistically significant only for NO<sub>2</sub>, as for allergic sensitization. The similarity of results according to allergic sensitization and according to asthma is probably due to the fact that allergic sensitization is strongly interrelated to asthma. Anyway, the association between air pollution exposure and rhinitis severity is most likely not confused by asthma status.

We found that a higher exposure to air pollution was associated with an increased severity of rhinitis among non-smokers but not among smokers. However, the estimates were of comparable magnitude or even higher in smokers than in non-smokers, and no interaction was found. These results are probably due to the fact that less than 20% of individuals were current smokers and therefore the sample size was probably small for such an evaluation. Similarly, we found that a higher exposure in air pollution was associated with an increased severity in ECRHS but not in EGEA, which represent around 20% of the individuals of our study. However, as EGEA is originally a case-control on asthma and thus have a high proportion of participants with asthma, results from the stratified analyses by study are in line with those from the analyses stratified by asthma.

We found similar results whether or not taking into account the city or including a random intercept for the city level, suggesting that adding the city level did not provide more information for the model and thus that the association between air pollution and severity of rhinitis does not change according to the city. Generally, our results were quite robust as estimates were similar in crude and adjusted analysis, whether taking the city into account or not.

The ARIA classification on severity was initially built for allergic rhinitis, but it may be extended to other phenotypes of rhinitis such as non-allergic rhinitis. Indeed, questions used to define severity are not specifically related to the allergic facet of the disease. Rhinitis is usually not defined by only one symptom, but by a combination of several symptoms characterizing the disease as a whole (1). We have therefore considered the score of severity in order to appraise the general effect of long-term air pollution on rhinitis severity. However, some symptoms may be more frequent in allergic rhinitis or non-allergic (8), and the effect of air pollutant on rhinitis severity may depend of the type of symptom of rhinitis. In our study, results differed according to the symptom and even if results were slightly stronger for “blocked nose”, no clear allergic or non-allergic pattern stood out.

Our results also differed according to the pollutant studied. Association between PM metrics and rhinitis severity increased gradually with levels of severity, whereas in the association between NO<sub>2</sub> exposure, effect size was the same whatever the levels. Both NO<sub>2</sub> and PM metrics are pollutants related to traffic, but their size and mechanisms of action are different, as well as how they can interact with pollen (30–32). The interaction between allergic sensitization and asthma status and NO<sub>2</sub> also supports this hypothesis. The potential

mechanisms of action suggested to explain the effects of air pollutants are related to oxidative stress (33), reactive oxygen species, apoptosis and inflammation (34). In our case, gaseous or particulate pollutants seem to both have a distinct effect on rhinitis severity, and this was confirmed by our bi-pollutant model. It is somehow surprising that associations were weaker or null for PM<sub>coarse</sub>, given that this PM fraction would be expected to have a higher nasal fractional deposition than PM<sub>2.5</sub>. Particulates of different aerodynamic diameters may lead to different inflammatory responses in the respiratory tract (35) and the mechanisms underlying the interaction between PM and the immune system still need to be elucidated and addressed clinically (36). Furthermore, the biological effects of particulates are based on their chemical compositions, which may depend on the diameter of particulates. We found no clear association between traffic metrics and severity of rhinitis, a result consistent with previous ESCAPE papers reporting associations between specific pollutants with asthma and lung function, but not with traffic metrics (37,38). All these results bring up the hypothesis that biological mechanisms by which air pollution may affect rhinitis are not the same depending on the pollutant as well as on the phenotype of rhinitis studied, and in particular according to allergic sensitization. Further studies filling the gap between air pollution exposure, biological markers of inflammation and phenotype of rhinitis are needed to better understand the underlying mechanisms of the general association.

In conclusion, using data from the 1,408 adults with rhinitis from two European studies on respiratory health, the present study showed that annual air pollution exposure was associated with increased severity of rhinitis, in particular for PM metrics. These results bring new insights into the management of rhinitis, a hidden major public health challenge, associated with substantial daily impairment and high cost to society. Finally, our results contribute to a better understanding of the environmental risk factors of this disease and re-emphasize the evidence that air pollution needs to be better controlled.

## References:

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008\*. *Allergy*. 2008 Apr;63(SUPPL. 86):8–160.
2. Katelaris CH, Lee BW, Potter PC, Maspero JF, Cingi C, Lopatin a, et al. Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America. *Clin Exp Allergy*. 2012 Feb;42(2):186–207.
3. Wang J, Engvall K, Smedje G, Norbäck D. Rhinitis, asthma and respiratory infections among adults in relation to the home environment in multi-family buildings in Sweden. *PLoS One*. 2014;9(8):24–6.
4. Bousquet J, Cauwenberge P Van. Allergic rhinitis and its impact on asthma. ARIA. In collaboration with the World Health Organization. *Prim Care Respir J*. 2002;11(1):18–9.
5. Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Impact of allergic rhinitis symptoms on quality of life in primary care. *Int Arch Allergy Immunol*. 2013;160(4):393–400.
6. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. *J Allergy Clin Immunol*. 2000 Nov;106(5):S201–5.
7. Papadopoulos NG, Bernstein JA, Demoly P, Dykewicz M, Fokkens W, Hellings PW, et al. Phenotypes and endotypes of rhinitis and their impact on management: A PRACTALL report. *Allergy Eur J Allergy Clin Immunol*. 2015;70(5).
8. Quillen DM, Feller DB. Diagnosing rhinitis: allergic vs. nonallergic. *Am Fam Physician*. 2006 May 1;73(9):1583–90.
9. Heinrich J. Air pollutants and primary allergy prevention. *Allergo J Int*. 2018 Feb 10;28(1):5–15.
10. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population-based study. *Lancet*. 2008 Sep 20;372(9643):1049–57.
11. Rage E, Siroux V, Künzli N, Pin I, Kauffmann F. Air pollution and asthma severity in adults. *Occup Environ Med*. 2009;66(3):182–8.
12. Guarnieri M, Balmes JR. Outdoor air pollution and asthma. *Lancet*. 2014;383(9928):1581–92.
13. Hajat S, Haines A, Atkinson RW, Bremner SA, Anderson HR, Emberlin J. Association between air pollution and daily consultations with general practitioners for allergic rhinitis in London, United Kingdom. *Am J Epidemiol*. 2001 Apr 1;153(7):704–14.
14. Zhang F, Wang W, Lv J, Krafft T, Xu J. Time-series studies on air pollution and daily outpatient visits for allergic rhinitis in Beijing, China. *Sci Total Environ*. 2011 Jun 1;409(13):2486–92.
15. Annesi-Maesano I, Rouve S, Desqueyroux H, Jankovski R, Klossek J-M, Thibaudon M, et al. Grass pollen counts, air pollution levels and allergic rhinitis severity. *Int Arch Allergy Immunol*. 2012;158(4):397–404.

16. Mady LJ, Schwarzbach HL, Moore JA, Boudreau RM, Kaffenberger TM, Willson TJ, et al. The association of air pollutants and allergic and nonallergic rhinitis in chronic rhinosinusitis. *Int Forum Allergy Rhinol.* 2018;8(3):369–76.
17. Burte E, Leynaert B, Bono R, Brunekreef B, Bousquet J, Carsin A-E, et al. Association between air pollution and rhinitis incidence in two European cohorts. *Environ Int.* 2018 Jun;115(March):257–66.
18. Kauffmann F. EGEA - descriptive characteristics. *Clin Exp Allergy.* 1999;29:17–21.
19. Kauffmann F, Dizier MH, Pin I, Paty E, Gormand F, Vervloet D, et al. Epidemiological study of the genetics and environment of asthma, bronchial hyperresponsiveness, and atopy: phenotype issues. *Am J Respir Crit Care Med.* 1997 Oct;156(4 Pt 2):S123-9.
20. Siroux V, Boudier A, Bousquet J, Bresson J-L, Cracowski J-L, Ferran J, et al. Phenotypic determinants of uncontrolled asthma. *J Allergy Clin Immunol.* 2009 Oct;124(4):681–7.e3.
21. Bouzigon E, Nadif R, Le Moual N, Dizier M-H, Aschard H, Boudier A, et al. Facteurs génétiques et environnementaux de l'asthme et de l'allergie : synthèse des résultats de l'étude EGEA. *Rev Mal Respir.* 2015 Oct;32(8):822–40.
22. Burney PG, Luczynska C, Chinn S, Jarvis D. The European Community Respiratory Health Survey. *Eur Respir J.* 1994 May 1;7(5):954–60.
23. Committee. ECRHSIS. The European Community Respiratory Health Survey II. *Eur Respir J.* 2002;20(5):1071–9.
24. Rouve S, Didier A, Demoly P, Jankowski R, Klossek JM, Annesi-Maesano I. Numeric score and visual analog scale in assessing seasonal allergic rhinitis severity. *Rhinology.* 2010;48(3):285–91.
25. Siroux V, Basagaña X, Boudier A, Pin I, Garcia-Aymerich J, Vesin A, et al. Identifying adult asthma phenotypes using a clustering approach. *Eur Respir J.* 2011 Aug;38(2):310–7.
26. Beelen R, Hoek G, Vienneau D, Eeftens M, Dimakopoulou K, Pedeli X, et al. Development of NO<sub>2</sub> and NO<sub>x</sub> land use regression models for estimating air pollution exposure in 36 study areas in Europe - The ESCAPE project. *Atmos Environ.* 2013;72:10–23.
27. Eeftens M, Beelen R, De Hoogh K, Bellander T, Cesaroni G, Cirach M, et al. Development of land use regression models for PM<sub>2.5</sub>, PM<sub>2.5</sub> absorbance, PM<sub>10</sub> and PM<sub>coarse</sub> in 20 European study areas; Results of the ESCAPE project. *Environ Sci Technol.* 2012;46(20):11195–205.
28. Basagaña X, Pedersen M, Barrera-Gómez J, Gehring U, Giorgis-Allemand L, Hoek G, et al. Analysis of multicentre epidemiological studies: contrasting fixed or random effects modelling and meta-analysis. *Int J Epidemiol.* 2018;47(4):1343–54.
29. de Hoogh K, Gulliver J, Donkelaar A van, Martin R V., Marshall JD, Bechle MJ, et al. Development of West-European PM<sub>2.5</sub> and NO<sub>2</sub> land use regression models incorporating satellite-derived and chemical transport modelling data. *Environ Res.* 2016;151(2):1–10.

30. D'Amato G, Pawankar R, Vitale C, Lanza M, Molino A, Stanziola A, et al. Climate Change and Air Pollution: Effects on Respiratory Allergy. *Allergy Asthma Immunol Res.* 2016;8(5):391.
31. D'Amato M, Cecchi C, Annesi-Maesano I, D'Amato G. News on Climate change, air pollution and allergic trigger factors of asthma. *J Investig Allergol Clin Immunol.* 2018;28(2).
32. Diaz-Sanchez D, Penichet-Garcia M, Saxon A. Diesel exhaust particles directly induce activated mast cells to degranulate and increase histamine levels and symptom severity. *J Allergy Clin Immunol.* 2000;106(6):1140–6.
33. Bates JT, Fang T, Verma V, Zeng L, Weber RJ, Tolbert PE, et al. Review of Acellular Assays of Ambient Particulate Matter Oxidative Potential: Methods and Relationships with Composition, Sources, and Health Effects. *Environ Sci Technol.* 2019 Apr 16;53(8):4003–19.
34. Jang A-S, Jun YJ, Park MK. Effects of air pollutants on upper airway disease. *Curr Opin Allergy Clin Immunol.* 2016 Feb;16(1):13–7.
35. Huang KL, Liu SY, Chou CCK, Lee YH, Cheng TJ. The effect of size-segregated ambient particulate matter on Th1/Th2-like immune responses in mice. *PLoS One.* 2017;12(2):1–16.
36. Wu J-Z, Ge D-D, Zhou L-F, Hou L-Y, Zhou Y, Li Q-Y. Effects of particulate matter on allergic respiratory diseases. *Chronic Dis Transl Med.* 2018;4(2):95–102.
37. Adam M, Schikowski T, Carsin a. E, Cai Y, Jacquemin B, Sanchez M, et al. Adult lung function and long-term air pollution exposure. ESCAPE: a multicentre cohort study and meta-analysis. *Eur Respir J.* 2015;45(1):38–50.
38. Jacquemin B, Siroux V, Sanchez M, Carsin A-E, Schikowski T, Adam M, et al. Ambient Air Pollution and Adult Asthma Incidence in Six European Cohorts (ESCAPE). *Environ Health Perspect.* 2015;123(6):613–21.

Figure legends

**Figure 1: Flow-chart of the participants**

**Figure 2: Associations between air pollutant metrics and severity of rhinitis**

Reference : low severity, Odds Ratio adjusted for age, sex, smoking status, asthma, allergic sensitization (and NO<sub>2</sub> background for traffic load and traffic Intensity), with city as a random intercept. Number reported below the pollutants correspond to the number of patients included in the adjusted analysis.

**Figure 3: Associations between air pollutant metrics and levels of severity score of rhinitis, among participants without allergic sensitization (A) and among participants with allergic sensitization (B)**

Reference: low severity, Odds Ratio adjusted for age, sex, smoking status, asthma (and NO<sub>2</sub> background for traffic load and traffic Intensity), with city as a random intercept. Number reported below the pollutants corresponds to the number of patients included in the adjusted analysis

Table 1 Characteristics of the participants, overall and by levels of score of severity

| Variable   | ALL<br>N=1408 | low severity<br>N= 418 | mild severity<br>N=417 | moderate<br>severity<br>N=251 | high severity<br>N=322 | p-value |
|--|---------------|------------------------|------------------------|-------------------------------|------------------------|---------|
| Score of severity,<br>median [q1-q3]                       | 4[2-6]        | 2[1-2]                 | 4[3-4]                 | 6[5-6]                        | 8[7-9]                 |         |
| Age, mean±sd   | 52.3±10.3     | 54.2±9.53              | 52.8±10.3              | 50.5±10.8                     | 50.5±10.6              | <0.001  |
| Study, % EGEA  | 19.0          | 12.0                   | 18.5                   | 23.1                          | 25.5                   | <0.001  |
| Sex=women, %   | 54.4          | 51.2                   | 51.8                   | 60.2                          | 57.5                   | 0.059   |
| Smoking status, %  |               |                        |                        |                               |                        |         |
| current  | 18.3          | 19.9                   | 17.3                   | 23.8                          | 13.0                   | 0.004   |
| ex-smoker  | 38.3          | 40.3                   | 41.5                   | 30.7                          | 37.8                   |         |
| never  | 43.4          | 39.8                   | 41.2                   | 45.6                          | 49.2                   |         |
| Educational level, %                                       |               |                        |                        |                               |                        | 0.386   |
| low  | 21.4          | 21.8                   | 17.8                   | 22.2                          | 25.2                   |         |
| medium   | 29.7          | 29.8                   | 31.2                   | 27.8                          | 29.0                   |         |
| high   | 48.9          | 48.4                   | 51.0                   | 50.0                          | 45.9                   |         |
| Asthma ever, %   | 28.2          | 18.0                   | 28.4                   | 30.9                          | 38.9                   | <0.001  |
| Asthma age of onset,<br>mean±sd                            | 16.9±13.9     | 17.1±13.9              | 18.5±14.7              | 16.2±13.8                     | 13.8±14.7              | 0.43    |
| Report of allergic rhinitis<br>or hay fever ever, %        | 58.8          | 34.6                   | 58.7                   | 69.9                          | 81.6                   | <0.001  |
| Allergic sensitization, %                                  | 47.2          | 35.4                   | 46.2                   | 46.7                          | 64.3                   | <0.001  |
| Frequency of the<br>symptoms=persistent, %                 | 29.4          | 21.9                   | 26                     | 30                            | 43.3                   | <0.001  |
| Medication for rhinitis in<br>the last 12 months=yes,<br>% | 42.0          | 16.7                   | 37.0                   | 52.7                          | 68.8                   | <0.001  |
| NO <sub>2</sub> , µg.m <sup>-3</sup> , mean±sd             | 29.9±14.6     | 28.2±14.1              | 30.5±14.9              | 30.5±15.1                     | 30.8±14.2              | 0.047   |
| PM <sub>10</sub> , µg.m <sup>-3</sup> , mean±sd            | 25.2±6.95     | 24.1±6.34              | 24.8±7.09              | 26.1±7.09                     | 26.7±7.21              | 0.0009  |
| PM <sub>2.5</sub> , µg.m <sup>-3</sup> , mean±sd           | 15.3±3.79     | 14.6±3.37              | 15.3±4.10              | 15.7±3.74                     | 15.9±3.81              | 0.0018  |
| Pmcoarse, µg.m <sup>-3</sup> ,<br>mean±sd                  | 10.1±3.91     | 9.77±3.80              | 9.85±3.67              | 10.4±3.95                     | 10.8±4.27              | 0.0231  |
| Traffic load, mean   | 1600627       | 1460000                | 1510000                | 1790000                       | 1750000                | 0.52    |
| Traffic intensity, mean                                    | 5624          | 4328                   | 5496                   | 7227                          | 6439                   | 0.0109  |
| Severity of runny nose                                     |               |                        |                        |                               |                        | <0.001  |
| no   | 26.6          | 57.7                   | 23.0                   | 11.6                          | 2.80                   |         |
| mild   | 37.1          | 37.8                   | 59.5                   | 35.1                          | 37.1                   |         |
| moderate/severe  | 36.2          | 4.60                   | 17.5                   | 53.4                          | 88.2                   |         |
| Severity of blocked nose                                   |               |                        |                        |                               |                        | <0.001  |
| no   | 32.5          | 72.7                   | 26.6                   | 14.3                          | 2.20                   |         |
| mild   | 25.3          | 21.8                   | 44.4                   | 20.3                          | 9.00                   |         |
| moderate/severe  | 42.2          | 5.50                   | 29.0                   | 65.3                          | 88.8                   |         |
| Severity of itchy nose                                     |               |                        |                        |                               |                        | <0.001  |
| no   | 44.7          | 82.5                   | 46.8                   | 27.9                          | 6.20                   |         |



|   |                 |      |      |      |      |      |        |
|---|-----------------|------|------|------|------|------|--------|
|   | mild            | 31.6 | 16.5 | 49.2 | 45.0 | 17.7 |        |
|   | moderate/severe | 23.7 | 1.00 | 4.10 | 27.1 | 76.1 |        |
| Severity of sneezing  |                 |      |      |      |      |      | <0.001 |
|   | no              | 30.4 | 60.8 | 28.8 | 16.7 | 3.70 |        |
|   | mild            | 37.8 | 36.4 | 57.1 | 38.7 | 14.0 |        |
|   | moderate/severe | 31.8 | 2.87 | 14.2 | 44.6 | 82.3 |        |
| q1= quartile 1, q3= quartile 3, sd= standard deviation, p-value of the overall difference between the 4 categories of severity of rhinitis, p-value overall |                 |      |      |      |      |      |        |

ECRHS III, participants from  
centers included in ESCAPE  
N=3541

→ Participants without rhinitis in the last 12 months  
(N=2131)

→ Participants without severity score (N=78)

→ Participants without NO<sub>2</sub> data (N=191)

N=1141


EGEA3, participants from centers  
included in ESCAPE  
N=980

→ Participants without rhinitis in the last 12  
months (N=540)


→ Participants without severity score (N=173)

N=267

N=1408



A



B

